regression in each of these subgroup analyses. Statistical analysis was performed using STATA, version 15.1 (StataCorp LLP). Results Characteristics of Study Cohort Overall characteristics of the study cohort are summarized in Table 1 . Most patients were
Search Results
Low Rates of Chemotherapy Use for Primary, High-Grade Soft Tissue Sarcoma: A National Cancer Database Analysis
Danielle S. Graham, Mykola Onyshchenko, Mark A. Eckardt, Benjamin J. DiPardo, Sriram Venigalla, Scott D. Nelson, Bartosz Chmielowski, Arun S. Singh, Jacob E. Shabason, Fritz C. Eilber, and Anusha Kalbasi
Rationing Cancer Care: A Survey Among the Members of the German Society of Hematology and Oncology
Stefan W. Krause, Jan Schildmann, Christian Lotze, and Eva C. Winkler
oncology (72%). Many respondents reported having cared for inpatients and outpatients in the previous 6 months. Table 1 summarizes the respondents' characteristics and practice settings. Prevalence, Rationing Strategies, and Rationales for
Rates of Menstrual History-Taking and Counseling With Anticancer Treatments Are Low: People Who Menstruate Deserve Gender-Specific Cancer Care
Verity Chadwick, Michaela Kim, Georgia Mills, Catherine Tang, Antoinette Anazodo, Rachel Dear, Rachael Rodgers, Orly Lavee, Samuel Milliken, Georgia McCaughan, John Moore, Barbara Withers, and Nada Hamad
to summarize the results. Results Participant Characteristics A total of 137 patients met the study inclusion criteria. Median age at diagnosis was 41 years (range, 19–49 years). The most common diagnosis was breast cancer (54
Are Surrogate Endpoints Unbiased Metrics in Clinical Benefit Scores of the ASCO Value Framework?
Sierra Cheng, Matthew C. Cheung, Di Maria Jiang, Erica McDonald, Vanessa S. Arciero, Doreen Anuli Ezeife, Amanda Rahmadian, Alexandra Chambers, Kelley-Anne Sabarre, Ambika Parmar, and Kelvin K.W. Chan
scoring. Of these 127 RCTs, 108 RCTs comprising 116 treatment comparisons reported HR OS and were therefore included in the primary analysis. Key characteristics of the included RCTs are described in Table 1 . Figure 1. Process of screening and scoring
Clinical Activity of Selitrectinib in a Patient With Mammary Analogue Secretory Carcinoma of the Parotid Gland With Secondary Resistance to Entrectinib
Vaia Florou, Christopher Nevala-Plagemann, Jonathan Whisenant, Patricia Maeda, Glynn W. Gilcrease, and Ignacio Garrido-Laguna
carcinomas of the breast. They share a lobulated pattern; express MUC1, MUC4, and mammaglobin 1 ; and are stained positive with periodic acid–Schiff and mucicarmine. In addition to morphology, a pathognomonic characteristic of MASC is the presence of the ETV
Mortality After Invasive Second Breast Cancers Following Prior Radiotherapy for DCIS
Puyao C. Li, Zilu Zhang, Angel M. Cronin, and Rinaa S. Punglia
the characteristics and prognosis of SBC. Patients and Methods Using the SEER database, 3,407 patients were identified who received BCS ± RT for primary DCIS in 2000 through 2013 and subsequently developed a stage I–III invasive SBC within the same
Treatment Patterns and Outcomes in Patients With Hepatocellular Carcinoma Stratified by Stage-Guided Treatment Categories
Kuan-Ling Kuo, David Stenehjem, Frederick Albright, Saurabh Ray, and Diana Brixner
at least 2 encounters in the EDW, with 1 encounter at least 30 days from the index date ( Figure 1 , available online, in this article, at JNCCN.org ). Demographic characteristics (age, sex, race, plan type, region) were recorded on index date and
Patient-Defined Goals and Preferences Among Adults With Advanced Neuroendocrine Tumors
Daneng Li, Can-Lan Sun, Heeyoung Kim, Christiana Crook, Ya-Han Zhang, Rebecca Allen, Richard Ballena, Shadman Hyder, Marianna Koczywas, Vincent Chung, Dean Lim, Vani Katheria, William Dale, and Gagandeep Singh
/treatment characteristics. The proportions and 95% confidence intervals of patients choosing survival, function/independence, freedom from pain, or freedom from symptoms as their most important treatment goal on the Health Outcomes Tool were calculated. Patient opinions on
Survival in Patients With Sentinel Node–Positive Melanoma With Extranodal Extension
Andrea Maurichi, Francesco Barretta, Roberto Patuzzo, Rosalba Miceli, Gianfranco Gallino, Ilaria Mattavelli, Consuelo Barbieri, Andrea Leva, Martina Angi, Francesco Baldo Lanza, Giuseppe Spadola, Mara Cossa, Francesco Nesa, Umberto Cortinovis, Laura Sala, Lorenza Di Guardo, Carolina Cimminiello, Michele Del Vecchio, Barbara Valeri, and Mario Santinami
predictors associated with a more aggressive clinical behavior in patients with positive SNs, particularly with regard to metastatic involvement of further non-SNs. Some of these analyses of factors for higher invasiveness focused on characteristics of the
Immune-Related Adverse Events Among COVID-19–Vaccinated Patients With Cancer Receiving Immune Checkpoint Blockade
Adam J. Widman, Bevin Cohen, Vivian Park, Tara McClure, Jedd Wolchok, and Mini Kamboj
-agent pembrolizumab. No patients experienced a flare of a prior irAE after vaccination. Table 2 compares characteristics of patients who did versus did not experience an irAE. No significant differences in baseline characteristics or treatment were seen between
